PARVB promotes malignant melanoma progression and is enhanced by hypoxic conditions

[1]  Cyrus Chargari,et al.  Advances in adoptive T-cell therapy for metastatic melanoma. , 2023, Current research in translational medicine.

[2]  Yueying Yang,et al.  Recent Advances in Perfluorocarbon-Based Delivery Systems for Cancer Theranostics. , 2023, Molecular pharmaceutics.

[3]  K. Mortezaee,et al.  The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  Partha Palit,et al.  Enhancement of immune surveillance in breast cancer by targeting hypoxic tumor endothelium: Can it be an immunological switch point? , 2023, Frontiers in Oncology.

[5]  Aruni Ghose,et al.  Melanoma-the therapeutic considerations in the clinical practice. , 2023, Annals of palliative medicine.

[6]  Yan Zhang,et al.  Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses. , 2022, Journal of hepatology.

[7]  V. Adam,et al.  Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape , 2022, Journal of Hematology & Oncology.

[8]  G. Semenza,et al.  Hypoxia-inducible factors: cancer progression and clinical translation , 2022, The Journal of clinical investigation.

[9]  N. Ahmad,et al.  Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter , 2022, Frontiers in Oncology.

[10]  Xiaochen Li,et al.  Hypoxia Induced Changes of Exosome Cargo and Subsequent Biological Effects , 2022, Frontiers in Immunology.

[11]  H. Hua,et al.  Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy , 2022, Journal of Hematology & Oncology.

[12]  B. Helmink,et al.  Hallmarks of response, resistance, and toxicity to immune checkpoint blockade , 2021, Cell.

[13]  R. Farré,et al.  Heterogeneity of Melanoma Cell Responses to Sleep Apnea-Derived Plasma Exosomes and to Intermittent Hypoxia , 2021, Cancers.

[14]  Zhi-qun Jiang,et al.  Construction of Novel Methylation-Driven Gene Model and Investigation of PARVB Function in Glioblastoma , 2021, Frontiers in Oncology.

[15]  Sidrah Shah,et al.  Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets , 2021, International journal of molecular sciences.

[16]  M. Ciesielka,et al.  The role of immunotherapy and molecular‑targeted therapy in the treatment of melanoma (Review). , 2021, Oncology Report.

[17]  Antonios Revythis,et al.  Unraveling the Wide Spectrum of Melanoma Biomarkers , 2021, Diagnostics.

[18]  M. Wangpaichitr,et al.  Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma , 2021, International journal of molecular sciences.

[19]  P. Pedrazzoli,et al.  Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need , 2021, Current Oncology Reports.

[20]  Qing Zhang,et al.  Hypoxia-Driven Effects in Cancer: Characterization, Mechanisms, and Therapeutic Implications , 2021, Cells.

[21]  N. Pavlidis,et al.  Melanoma of Unknown Primary: New Perspectives for an Old Story. , 2020, Critical reviews in oncology/hematology.

[22]  H. Papadaki,et al.  Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival , 2020, Journal of Molecular Histology.

[23]  J. Melrose,et al.  Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan , 2020, Frontiers in Oncology.

[24]  Lu Jiang,et al.  Glutathione peroxidase 3 (GPX3) suppresses the growth of melanoma cells through reactive oxygen species (ROS)‐dependent stabilization of hypoxia‐inducible factor 1‐α and 2‐α , 2019, Journal of cellular biochemistry.

[25]  T. Soga,et al.  MITF controls the TCA cycle to modulate the melanoma hypoxia response , 2019, Pigment cell & melanoma research.

[26]  T. Kang,et al.  Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1-α dependent PDK-1 signaling pathway , 2019, Redox biology.

[27]  Hai-rong Chen,et al.  Knockdown of FBXO22 inhibits melanoma cell migration, invasion and angiogenesis via the HIF-1α/VEGF pathway , 2019, Investigational New Drugs.

[28]  Sunghoon Kim,et al.  HIF1α‐mediated AIMP3 suppression delays stem cell aging via the induction of autophagy , 2019, Aging cell.

[29]  Myung-Chul Kim,et al.  Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma , 2018, BMC Cancer.

[30]  Q. Ding,et al.  Differential expressions of integrin-linked kinase, β-parvin and cofilin 1 in high-fat diet induced prostate cancer progression in a transgenic mouse model , 2018, Oncology letters.

[31]  S. Letautiene,et al.  Analysis of prognostic factors for melanoma patients , 2017, Acta medica Lituanica.

[32]  C. Longo,et al.  Hypoxia‐Inducible Factor‐1α and CD271 inversely correlate with melanoma invasiveness , 2015, Experimental dermatology.

[33]  Hiroshi Watanabe,et al.  PARVB overexpression increases cell migration capability and defines high risk for endophytic growth and metastasis in tongue squamous cell carcinoma , 2014, British Journal of Cancer.

[34]  J. Handa,et al.  Hypoxia Promotes Uveal Melanoma Invasion through Enhanced Notch and MAPK Activation , 2014, PloS one.

[35]  M. Nguyen,et al.  Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases. , 2013, Gynecologic oncology.

[36]  E. Giannoni,et al.  HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. , 2011, Free radical biology & medicine.

[37]  J. Guan,et al.  Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. , 2011, Advanced drug delivery reviews.

[38]  Yu Jin Lee,et al.  Caveolin‐1 and integrin β1 regulate embryonic stem cell proliferation via p38 MAPK and FAK in high glucose , 2011, Journal of cellular physiology.

[39]  D. Trisciuoglio,et al.  455 Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90 , 2010 .

[40]  J. Beaulieu,et al.  Integrin-linked kinase regulates migration and proliferation of human intestinal cells under a fibronectin-dependent mechanism , 2010, Journal of cellular physiology.

[41]  Mark J. Bowser,et al.  Parvin-β Inhibits Breast Cancer Tumorigenicity and Promotes CDK9-Mediated Peroxisome Proliferator-Activated Receptor Gamma 1 Phosphorylation , 2007, Molecular and Cellular Biology.

[42]  A. Rustgi,et al.  β-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer , 2004, Oncogene.

[43]  Delphine J. Lee,et al.  Melanoma Risk Factors and Prevention , 2020 .